Replies to post #331108 on NorthWest Biotherapeutics Inc (NWBO)

[marzan]

Yes Gary, this paxalisib, a PI3 cell disorder inhibitor, developed to treat cancer and kind of gave up by Genentech is now being tested by Karzia, and like you said the benefit is when compared with DcVaxL is like between a valley and Himalayas. But I see Karzia is gaining traction for a few month improvement shown in Phase 2. A few months Vs a few years, I think DcVax is unbeatable by any pharma including BPs. We are golden, just can't wait for TLD! Go NWBO!!

[MarkoMD]

Ski, I believe those are pediatric patients, age 3-16 years. Peds GBM has always been a different animal with a much more favorable outcomes in general.

[marzan]

See KZIA (Karzia Therapautics) only improved 2 months from the standard therapy in their phase 2 trial and the stock is doing like 1000s of % higher. We are not 2 months but minimum 2 yrs improvement and plus in phase 3. We should go 10, 20 times when TLD is out. Just hang on Longs.

https://finance.yahoo.com/quote/KZIA?ltr=1